annual cash & cash equivalents:
$233.00M-$18.10M(-7.21%)Summary
- As of today (September 17, 2025), NBIX annual cash & cash equivalents is $233.00 million, with the most recent change of -$18.10 million (-7.21%) on December 31, 2024.
- During the last 3 years, NBIX annual cash & cash equivalents has fallen by -$107.80 million (-31.63%).
- NBIX annual cash & cash equivalents is now -31.63% below its all-time high of $340.80 million, reached on December 31, 2021.
Performance
NBIX Cash and cash equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly cash & cash equivalents:
$975.60M+$32.10M(+3.40%)Summary
- As of today (September 17, 2025), NBIX quarterly cash & cash equivalents is $975.60 million, with the most recent change of +$32.10 million (+3.40%) on June 30, 2025.
- Over the past year, NBIX quarterly cash & cash equivalents has dropped by -$63.30 million (-6.09%).
- NBIX quarterly cash & cash equivalents is now -20.55% below its all-time high of $1.23 billion, reached on September 30, 2024.
Performance
NBIX quarterly cash & cash equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Cash and cash equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
NBIX Cash and cash equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -7.2% | -6.1% |
| 3 y3 years | -31.6% | +50.5% |
| 5 y5 years | +107.5% | +2.9% |
NBIX Cash and cash equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -31.6% | at low | -20.6% | +50.5% |
| 5 y | 5-year | -31.6% | +107.5% | -20.6% | +50.5% |
| alltime | all time | -31.6% | +1962.0% | -20.6% | >+9999.0% |
NBIX Cash and cash equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Jun 2025 | - | $975.60M(+3.4%) |
| Mar 2025 | - | $943.50M(-12.3%) |
| Dec 2024 | $233.00M(-7.2%) | $1.08B(-12.4%) |
| Sep 2024 | - | $1.23B(+18.2%) |
| Jun 2024 | - | $1.04B(-14.2%) |
| Mar 2024 | - | $1.21B(+17.4%) |
| Dec 2023 | $251.10M(-4.5%) | $1.03B(-5.8%) |
| Sep 2023 | - | $1.10B(+12.1%) |
| Jun 2023 | - | $976.70M(+9.2%) |
| Mar 2023 | - | $894.60M(-9.6%) |
| Dec 2022 | $262.90M(-22.9%) | $989.30M(+23.8%) |
| Sep 2022 | - | $799.40M(+23.3%) |
| Jun 2022 | - | $648.30M(-2.5%) |
| Mar 2022 | - | $664.90M(-6.5%) |
| Dec 2021 | $340.80M(+82.1%) | $711.30M(-7.1%) |
| Sep 2021 | - | $765.90M(-13.4%) |
| Jun 2021 | - | $884.90M(+1.3%) |
| Mar 2021 | - | $873.70M(+9.1%) |
| Dec 2020 | $187.10M(+66.6%) | $801.00M(-15.2%) |
| Sep 2020 | - | $944.70M(-0.4%) |
| Jun 2020 | - | $948.30M(+22.9%) |
| Mar 2020 | - | $771.70M(+15.1%) |
| Dec 2019 | $112.30M(-20.8%) | $670.52M(-0.0%) |
| Sep 2019 | - | $670.63M(+8.2%) |
| Jun 2019 | - | $619.98M(+18.3%) |
| Mar 2019 | - | $524.07M(-19.5%) |
| Dec 2018 | $141.71M(-44.4%) | $650.91M(+2.5%) |
| Sep 2018 | - | $635.34M(+24.9%) |
| Jun 2018 | - | $508.74M(+10.5%) |
| Mar 2018 | - | $460.48M(-10.7%) |
| Dec 2017 | $254.71M(+205.9%) | $515.93M(+1.0%) |
| Sep 2017 | - | $511.02M(-2.7%) |
| Jun 2017 | - | $525.02M(+122.9%) |
| Mar 2017 | - | $235.58M(-23.4%) |
| Dec 2016 | $83.27M(+12.2%) | $307.35M(-12.9%) |
| Sep 2016 | - | $353.04M(-8.9%) |
| Jun 2016 | - | $387.40M(+1.5%) |
| Mar 2016 | - | $381.52M(+0.6%) |
| Dec 2015 | $74.19M(+139.2%) | $379.19M(+0.6%) |
| Sep 2015 | - | $376.85M(-2.0%) |
| Jun 2015 | - | $384.72M(+4.0%) |
| Mar 2015 | - | $370.01M(+90.9%) |
| Dec 2014 | $31.01M(-30.8%) | $193.81M(+7.9%) |
| Sep 2014 | - | $179.67M(-7.7%) |
| Jun 2014 | - | $194.66M(-11.5%) |
| Mar 2014 | - | $219.86M(+50.9%) |
| Dec 2013 | $44.79M | $145.74M(-7.1%) |
| Sep 2013 | - | $156.91M(+2.1%) |
| Jun 2013 | - | $153.70M(-2.9%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2013 | - | $158.23M(-8.5%) |
| Dec 2012 | $63.75M(+27.2%) | $173.01M(-0.5%) |
| Sep 2012 | - | $173.96M(-2.0%) |
| Jun 2012 | - | $177.54M(-2.0%) |
| Mar 2012 | - | $181.09M(+125.0%) |
| Dec 2011 | $50.11M(-7.3%) | - |
| Dec 2010 | $54.05M(+44.8%) | - |
| Dec 2009 | $37.33M(-45.5%) | - |
| Dec 2008 | $68.47M(-31.3%) | $80.47M(-55.1%) |
| Dec 2007 | $99.66M(+23.1%) | $179.38M(+43.7%) |
| Sep 2007 | - | $124.83M(-15.3%) |
| Jun 2007 | - | $147.30M(-11.7%) |
| Mar 2007 | - | $166.79M(-8.7%) |
| Dec 2006 | $80.98M(+62.1%) | $182.60M(-8.6%) |
| Sep 2006 | - | $199.78M(-14.7%) |
| Jun 2006 | - | $234.32M(-11.4%) |
| Mar 2006 | - | $264.49M(-3.1%) |
| Dec 2005 | $49.95M(-18.2%) | $273.07M(-6.1%) |
| Sep 2005 | - | $290.84M(+19.6%) |
| Jun 2005 | - | $243.27M(-25.0%) |
| Dec 2004 | $61.03M(-42.3%) | - |
| Sep 2004 | - | $324.35M(-0.7%) |
| Jun 2004 | - | $326.54M(-12.2%) |
| Mar 2004 | - | $371.73M(-18.0%) |
| Dec 2003 | $105.85M(+138.9%) | $453.17M(+2.3%) |
| Sep 2003 | - | $442.78M(+62.3%) |
| Jun 2003 | - | $272.81M(-11.5%) |
| Mar 2003 | - | $308.24M(+98.0%) |
| Dec 2002 | $44.31M(-73.0%) | - |
| Dec 2001 | $163.89M(+677.5%) | - |
| Mar 2001 | - | $155.69M(-5.5%) |
| Dec 2000 | $21.08M(-1.0%) | $164.67M(+107.3%) |
| Sep 2000 | - | $79.45M(-0.5%) |
| Jun 2000 | - | $79.82M(-11.1%) |
| Mar 2000 | - | $89.75M(+84.9%) |
| Dec 1999 | $21.30M(+82.1%) | - |
| Sep 1999 | - | $48.54M(-8.6%) |
| Jun 1999 | - | $53.10M(-8.4%) |
| Mar 1999 | - | $57.94M(-12.3%) |
| Dec 1998 | $11.70M(-25.9%) | - |
| Sep 1998 | - | $66.09M(+1.4%) |
| Jun 1998 | - | $65.20M(-5.4%) |
| Mar 1998 | - | $68.90M(+336.1%) |
| Dec 1997 | $15.80M(+39.8%) | $15.80M(+4.6%) |
| Sep 1997 | - | $15.10M(-34.1%) |
| Jun 1997 | - | $22.90M(+218.1%) |
| Mar 1997 | - | $7.20M(-36.3%) |
| Dec 1996 | $11.30M | $11.30M(+56.9%) |
| Sep 1996 | - | $7.20M(-66.8%) |
| Jun 1996 | - | $21.70M |
FAQ
- What is Neurocrine Biosciences, Inc. annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Neurocrine Biosciences, Inc.?
- What is Neurocrine Biosciences, Inc. annual cash & cash equivalents year-on-year change?
- What is Neurocrine Biosciences, Inc. quarterly cash & cash equivalents?
- What is the all time high quarterly cash & cash equivalents for Neurocrine Biosciences, Inc.?
- What is Neurocrine Biosciences, Inc. quarterly cash & cash equivalents year-on-year change?
What is Neurocrine Biosciences, Inc. annual cash & cash equivalents?
The current annual cash & cash equivalents of NBIX is $233.00M
What is the all time high annual cash & cash equivalents for Neurocrine Biosciences, Inc.?
Neurocrine Biosciences, Inc. all-time high annual cash & cash equivalents is $340.80M
What is Neurocrine Biosciences, Inc. annual cash & cash equivalents year-on-year change?
Over the past year, NBIX annual cash & cash equivalents has changed by -$18.10M (-7.21%)
What is Neurocrine Biosciences, Inc. quarterly cash & cash equivalents?
The current quarterly cash & cash equivalents of NBIX is $975.60M
What is the all time high quarterly cash & cash equivalents for Neurocrine Biosciences, Inc.?
Neurocrine Biosciences, Inc. all-time high quarterly cash & cash equivalents is $1.23B
What is Neurocrine Biosciences, Inc. quarterly cash & cash equivalents year-on-year change?
Over the past year, NBIX quarterly cash & cash equivalents has changed by -$63.30M (-6.09%)